Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06770556

Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study

An Investigation of TMS Effects Using Magnetoencephalography (MEG) Among Individuals With and Without Heavy Alcohol Use

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
10 (estimated)
Sponsor
Wake Forest University Health Sciences · Academic / Other
Sex
All
Age
21 Years – 65 Years
Healthy volunteers
Accepted

Summary

Alcohol use disorder (AUD) is a complex chronic brain disease characterized by compulsive alcohol use, loss of control over drinking, and negative emotional states. Extensive research has identified the general neural circuitry underlying AUD. There is an exciting opportunity to intervene in AUD using neuromodulation. Transcranial magnetic stimulation (TMS) offers a non-invasive method to modulate brain activity, making it a promising tool for investigating, modulating, and potentially treating AUD. However, the precise effects of TMS on neural circuits involved in AUD and the mechanisms underlying these effects must first be understood. Magnetoencephalography (MEG) is a neuroimaging method that provides direct measurement of brain activity within neural circuits with high temporal resolution. Critically, MEG can measure brain activity in a wide range of frequencies that are consistent with those targeted by TMS. The goal of this proposal is therefore to collect preliminary and feasibility data to support a future NIH grant application that would use MEG to investigate TMS effects in individuals with AUD (iAUD).

Detailed description

This proposal uses a mixed, between-group, within-subject design. The study will investigate the acute effects of different TMS pulse sequences in participants without AUD (non-AUD), and compare active/sham iTBS across non-AUD and AUD. On each study day, participants will complete a pre-TMS baseline MEG scan (10 min resting state), followed by a TMS pulse sequence, then complete 3 more MEG scans (immediately post-TMS, 1 hour post-TMS, and 2 hours post-TMS). Each TMS pulse sequence will be administered on a separate day and will be matched by the number of pulses administered (1200 pulses) and the total duration of administration time (20 min). The sham condition will control for auditory and sensory side effects associated with TMS. TMS will be applied to the left DLPFC, identified by the EEG F3 coordinate. Participants will either complete 4 study visits (n = 5) and receive 1 Hz, 10 Hz, iTBS, and sham, each on a separate day; or participants will complete 2 study visits (n = 5) and receive iTBS and sham, each on a separate day. Participants will also receive a structural MRI scan in order to map the MEG outcome data onto their own anatomical brain image.

Conditions

Interventions

TypeNameDescription
DEVICESham iTBSParticipants will receive sham iTBS
DEVICEActive iTBSParticipants will receive active iTBS
DEVICE10 Hz TMSParticipant will receive 10 Hz TMS
DEVICE1 Hz TMSParticipant will receive 1 Hz TMS

Timeline

Start date
2025-03-21
Primary completion
2026-12-31
Completion
2026-12-31
First posted
2025-01-13
Last updated
2026-04-17

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT06770556. Inclusion in this directory is not an endorsement.